{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By DAVID GELLES", "person": [{"rank": 1, "role": "reported", "firstname": "David", "organization": "", "lastname": "GELLES"}]}, "abstract": "Valeant Pharmaceuticals intends to work with Pershing Square Capital Management and top shareholders to raise bid for Salix Pharmaceuticals to above $160 per share in cash.", "type_of_material": "News", "word_count": "720", "lead_paragraph": "The company is said to be teaming up with shareholders including Pershing Square Capital Management to bring its offer above $160 a share.", "pub_date": "2015-03-14T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant Said to Be Planning to Raise Its Bid for Salix Pharmaceuticals", "print_headline": "Business Briefing; Valeant Prepares New Salvo in War for Drug Maker"}, "snippet": "The company is said to be teaming up with shareholders including Pershing Square Capital Management to bring its offer above $160 a share.", "multimedia": [{"height": 126, "url": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/03/14/business/dealbook/valeant-said-to-be-planning-to-raise-its-bid-for-salix-pharmaceuticals.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "11", "is_major": "N", "value": "Ackman, William A", "name": "persons"}, {"rank": "12", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "2", "is_major": "Y", "value": "Pershing Square Capital Management", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Salix Pharmaceuticals Ltd", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Hedge Funds", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Actavis PLC", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "Allergan Inc", "name": "organizations"}, {"rank": "9", "is_major": "N", "value": "Endo International PLC", "name": "organizations"}, {"rank": "10", "is_major": "N", "value": "ValueAct Capital Partners", "name": "organizations"}], "blog": [], "_id": "55031f6138f0d835da194e6d", "source": "The New York Times"}